title: [Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].
abstract: Findings in epigenetic changes in meylodysplastic syndromes (MDS) and the development of demethylating drugs provide a new approach to the treatment of MDS. We used standard-dose decitabine for treatment of MDS in an elderly patient with an International Prostate Symptom Score (IPSS) of moderate risk group 2, and achieved a complete response in the first course. We report our experience with this case and review the relevant literatures.
authors.affiliation: Huiqiao Department, Southern Medical University, Guangzhou, China. xiaoya_729@yahoo.com.cn
authors.forename: Ya
authors.initials: Y
authors.lastname: Gao
authors.forename: Baohong
authors.initials: B
authors.lastname: Ping
authors.forename: Shuyun
authors.initials: S
authors.lastname: Zhou
mesh_terms: D001374:Azacitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D000077209:Decitabine; D005260:Female; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
chemical_list: D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine